

30 August 2016

ASX Code: MXC

Q&A with Nativ Segev, MGC Pharmaceuticals Managing Director

MGC Pharmaceuticals Ltd (ASX:MXC or “the Company”) is pleased to advise MXC shareholders of today’s Finfeed publication of a Q&A article with Managing Director, Mr Nativ Segev, on the Company’s vision for its Australian strategy and commercialisation of the MXC business into the European and Asia/Pacific regions.

The Q&A article is available to be viewed via a link on the Company’s website:

<http://mgcpharma.com.au/#MediaNews>

-Ends-

For further information, please contact:

Media Enquiries

Andrew Ramadge
Senior Account Manager
Media and Capital Partners
+61 475 797 471
andrew.ramadge@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 9389 2000
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value add industries, as demonstrated with MGC Derma Cannabidiol based (CBD) cosmetics line.